52601-89-5

Usage

Uses

Used in Pharmaceutical Industry:
5-Pyrimidinol, 4-amino(7CI,9CI) is used as an intermediate in the synthesis of pharmaceuticals for its potential therapeutic applications. Its unique structure allows it to be a key component in the development of new drugs, particularly in the field of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Pyrimidinol, 4-amino(7CI,9CI) serves as a building block in the creation of various agrochemicals. Its role in this industry is crucial for the development of effective and environmentally friendly products.
Used in Material Science:
5-Pyrimidinol, 4-amino(7CI,9CI) is used as a key component in the production of dyes, polymers, and plastics. Its presence in these materials contributes to their color, stability, and other properties, making it an essential part of the material science field.
Used in Research and Development:
5-Pyrimidinol, 4-amino(7CI,9CI) is also utilized in research and development for exploring its potential biological activities. Scientists are interested in 5-Pyrimidinol, 4-amino- (7CI,9CI) due to its possible applications in medicine and other areas, making it a valuable subject of study.

Upstream product

• 695-86-3 amino-4 methoxy-5 pyrimidine 

Downstream Products

• 129249-41-8 2-methyloxazolo<4,5-d>pyrimidine 
• 42850-93-1 oxazolo<4,5-d>pyrimidine 
• 1188498-90-9 3-(oxazolo[4,5-d]pyrimidin-2-yl)phenol 

Relevant academic research and scientific papers

Heterocyclic compound used as MNK inhibitor

The invention relates to a heterocyclic compound, a pharmaceutical composition containing the heterocyclic compound, a preparation method thereof, and application thereof used as a mitogen activated protein kinase interacting kinase 1 and 2-MNK1/MNK2 inhibitor. The inhibitor is the heterocyclic compound as shown in the formula (I), or its pharmaceutically acceptable salt, prodrug, solvent compound, polycrystal, isomer, stable isotope derivative or a pharmaceutical composition containing the heterocyclic compound. The compound of the invention can be used for treating or preventing MNK-mediatedrelated diseases, such as cancers.

PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS

Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Development of a Scalable Synthesis of 4-Aminopyrimidin-5-ol, a Versatile Intermediate

A robust process for the preparation of multigram quantities of 4-aminopyrimidin-5-ol (5) in good yield from an inexpensive and readily available pyrimidine starting material is described. An initial evaluation of the reported literature route for this material utilizing a de novo pyrimidine synthesis provided safety concerns over the scalability of several intermediates. In addition, a number of steps proceeded in mediocre yield, and involved chromatographic separations for the desired products. The newly developed route mitigates the safety concerns, reduces the number of steps from five to three, avoids column chromatography, leads to an 8-fold improvement in yield, and utilizes reagents, which are recognized to be more environmentally benign.

Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields

Fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) are the main enzymes responsible for the hydrolysis of endogenous cannabinoids N-arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), respectively. Phenyl alkylcarbamates are FA